Archives
1 / 651
General, Mutual Funds
The Best ELSS Mutual Fund to Invest in 2025
ELSS funds remain a popular tax-saving investment under Section 80C, offering up to ₹1,50,000 in deductions (under the old tax regime) while providing ...
Stocks
Ganesh Housing: A GARP Opportunity
Ganesh Housing, a three-decade-old real estate player based in Ahmedabad, stands out with industry-leading margins driven by its 500-acre land bank and ...
General
Why is IndusInd Bank under pressure
IndusInd Bank’s stock is under pressure amid concerns over its derivative hedging strategy, which created an accounting mismatch between internal and ...
General
Alternative MF Picks for the Focused Portfolio
As you may already know, we will be sunsetting our research services in September 2025, also marking the end of all our premium portfolios including the ...
Stocks
Zaggle: Smarter Spend Management for Businesses
Zaggle is an innovative fintech SaaS company specializing in expense management, transforming how businesses streamline payments and manage vendor relations. ...
Stocks
Cracking the Patent Code: Natco’s Winning Formula
Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term ...
Stocks
TARIL: The Pickaxe and Shovel Play in India’s Energy Transformation
TARIL is one of the leading transformer manufacturers in India, and with the country’s growing power demand, the company is well-positioned to play a crucial ...
Premium Portfolio
In Earnings We Trust: 2024 Focused Portfolio Review
For the calendar year 2024, the Focused portfolio is up 29.4%, compared to the Nifty 50’s 8.7% and the Nifty 500’s 14.8%. We started 2024 on a ...
CM Strategy, General
Capitalmind Nifty No Downside Strategy: 2024 Performance Review
Capitalmind Nifty No Downside Strategy aims to capture 'almost' all the upside of the Nifty while minimizing downside risk through a combination of ...
Stocks
Jubilant Pharmova: At the Crossroads of Change
Jubilant Pharmova is a multifaceted pharma player, standing amidst a blend of growth and transformation. While some its segments are showing robust growth ...
